Later Development Manufacturers at this stage have an opportunity to take a strategic look at how preliminary clinical trial results address the unmet need in the market and how this may influence reimbursement and access at launch. Xcenda recommends manufacturers take a proactive approach to evaluating the payer and reimbursement landscape, forecasting provider uptake, assessing product risk, and developing a health outcomes strategy. Accelerate commercial opportunities with the following key services: Conduct a reimbursement landscape assessmentAnalyze the reimbursement rates of competitive products, consider how sites of care and distribution may impact patient access, review your coding strategy, and apply these findings to prioritize critical steps leading up to product launch.Read MoreAnalyze provider insights with Challenging Cases®Take a prospective look at how patterns of care would change with the introduction of a new therapy. Forecast projected uptake by studying clinicians' response to clinical trial data.Read MoreDevelop a risk management strategyReview phase 2 or interim phase 3 trial results to prepare for anticipated REMS discussions with the FDA. Position your product for less-stringent requirements while still ensuring safe use.Read MoreContract HEOR professionalsAccess the HEOR experts you need to ramp up for launch. Flexible contract staff can develop data for field teams, design and implement a publication strategy, or support the ongoing development of the product value proposition—all in coordination with your internal stakeholders.Read More Later Development: Additional ServicesExpand AllCollapse AllGather payer insightsMoreGather payer insights Test the anticipated product profile from interim phase 3 trial results. Assess whether payers value the product's potential features and benefits. Learn how changing market dynamics, including reimbursement rates, may impact product uptake at launch.Develop a managed markets strategyMoreDevelop a managed markets strategy Ensure your product will have a defensible value proposition at launch by clearly assessing the market value drivers before your product is introduced. Learn more about our payer value diagnostic methodology.Develop a compendia strategyMoreDevelop a compendia strategy Conduct a compendia analysis upon publication of phase 2 and 3 studies. Determine if, and to which compendia, the data should be submitted for review.